<DOC>
	<DOCNO>NCT00450593</DOCNO>
	<brief_summary>RATIONALE : Identifying gene mutation risk factor patient melanoma family history hereditary melanoma may help doctor identify person risk melanoma type cancer . It may also help study cancer future . PURPOSE : This clinical trial study gene mutation patient melanoma family history hereditary melanoma .</brief_summary>
	<brief_title>Identifying Gene Mutations Patients With Melanoma Families With History Hereditary Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence etiologic significance variant know melanoma susceptibility gene ( MSGs ) family multiple case melanoma . - Determine proportion multiple-case family explain high-penetrance mutation know MSGs . - Determine proportion multiple-case family explain mutation whether varies latitude , surrogate ultraviolet exposure , number affect relative , average age onset melanoma relative , presence multiple primary melanoma , family-specific variable . - Determine penetrance MSG mutation family . - Determine penetrance varies age , sex , birth cohort . - Determine penetrance varies gene involve nature mutation . - Assess penetrance mutation also deleterious effect alternative splice product , p14ARF . - Determine whether carrier MSGs increase susceptibility type cancer . - Determine risk type cancer mutation carrier . - Determine environmental exposure , particular sun exposure , modify risk melanoma MSG mutation carrier . - Determine cutaneous phenotype correlate melanoma risk family . - Correlate cutaneous phenotype presence MSG variant . - Determine effect covariates , sun exposure presence allele putative modify gene ( e.g. , MC1R CDKN2A ) , phenotype . - Determine modifier gene , control pigmentation skin , therefore sun susceptibility , modify risk MSG mutation carrier . - Identify histopathological correlate MSG status primary tumor arise melanoma-susceptible individual family . - Identify histopathological correlate primary melanoma carrier MSG mutation covariates . OUTLINE : This case-control , multicenter study . Participants complete 2 questionnaire assist creation expansion family pedigree . Blood sample examine melanoma susceptibility gene mutation , include CDK4 CDKN2A . Participants also examine mole photograph . Physical variable ( e.g. , skin , eye , hair pigmentation ) sun damage ( solar lentigo freckle ) also note . If available , tissue sample examine Clark level , Breslow thickness , frequency mitoses . Peri-lesional skin tumor examine p53 stain . Participants follow periodically monitor cancer development . Peer review funded endorsed Cancer Research UK PROJECTED ACCRUAL : A total 5,000 participant accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets one follow criterion : Prior multiple primary melanoma Histological sample available Family history melanoma , melanoma two firstdegree relative ( e.g. , case melanoma mother son two brother two cousin ) Family history melanoma , three individual ( relationship ) melanoma PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>melanoma</keyword>
	<keyword>hereditary multiple melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage 0 melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IA melanoma</keyword>
	<keyword>stage IB melanoma</keyword>
	<keyword>stage IIA melanoma</keyword>
	<keyword>stage IIB melanoma</keyword>
	<keyword>stage IIC melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>